Trial Profile
A Phase IB/II Study of Blinatumomab in Patients With Pre B-cell Acute Lymphoblastic Leukemia (ALL) and B-cell Non-Hodgkin Lymphoma (NHL) as Post-allogeneic Stem Cell Transplant (Allo-HSCT) Remission Maintenance
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Dexamethasone
- Indications Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results(n=42) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 24 May 2023 Status changed from recruiting to active, no longer recruiting.
- 28 May 2020 Planned number of patients changed from 12 to 64.